AGIO - CIK 0001439222
AGIOS PHARMACEUTICALS, INC. (AGIO) reported revenue of $54.03M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $54.03M | +48.0% |
| FY 2024 | $36.50M | +36.1% |
| FY 2023 | $26.82M | +88.4% |
| FY 2022 | $14.24M | - |
| FY 2021 | $0.00 | - |
| FY 2020 | $0.00 | -100.0% |
| FY 2019 | $117.91M | +24.9% |
| FY 2018 | $94.39M | +119.4% |
| FY 2017 |
AGIOS PHARMACEUTICALS, INC. (AGIO) reported revenue of $54.03M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, AGIOS PHARMACEUTICALS, INC.'s revenue grew from $21.84M to $54.03M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $43.01M |
| -38.5% |
| FY 2016 | $69.89M | +18.2% |
| FY 2015 | $59.12M | -9.5% |
| FY 2014 | $65.36M | +155.8% |
| FY 2013 | $25.55M | +1.8% |
| FY 2012 | $25.11M | +15.0% |
| FY 2011 | $21.84M | - |